(Total Views: 883)
Posted On: 02/29/2020 9:30:49 PM
Post# of 36563
https://microcapdaily.com/the-steady-rise-of-...bt/125213/
Currently trading at a $29 million market valuation GNBT is fully reporting and has $52 million in assets including $38 million in goodwill and over $24 million in current liabilities. The Company also boasts strong sales reporting $721k in revenues for the 3 months ended October 31, 2019. GNBT just reported the successful completion of the FINRA review process for the dividend and the Company just recieved a contract from chinese partners to develope a COVID-19 Vaccine using li-key peptide vaccines which includes an upfront payment of $1 million to initiate the project work in the United States, a $5 million licensing fee for the Ii-Key technology, payment by the Chinese consortium for all costs and expenses related to the development of a COVID-19 vaccine, and a 20% royalty on each dose of vaccine produced. We will be updating GNBT as events unfold so make sure you are subscribed to Microcapdaily so you know what is going on with GNBT.
Currently trading at a $29 million market valuation GNBT is fully reporting and has $52 million in assets including $38 million in goodwill and over $24 million in current liabilities. The Company also boasts strong sales reporting $721k in revenues for the 3 months ended October 31, 2019. GNBT just reported the successful completion of the FINRA review process for the dividend and the Company just recieved a contract from chinese partners to develope a COVID-19 Vaccine using li-key peptide vaccines which includes an upfront payment of $1 million to initiate the project work in the United States, a $5 million licensing fee for the Ii-Key technology, payment by the Chinese consortium for all costs and expenses related to the development of a COVID-19 vaccine, and a 20% royalty on each dose of vaccine produced. We will be updating GNBT as events unfold so make sure you are subscribed to Microcapdaily so you know what is going on with GNBT.
(1)
(0)
